Fatigue News and Research

RSS

Objective response rate promising after crizotinib for NSCLC

More than half of the latest evaluated participants from the ongoing phase II PROFILE 1005 trial of crizotinib against ALK-positive advanced non-small-cell lung cancer, achieved an objective tumor response, report researchers.

14 Sep 2012

Nationwide Children's Hospital introduces Concussion ToolKit for student-athletes

According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.

13 Sep 2012

Researchers gain new insight into regulation of adult nerve cell generation in the hypothalamus

Researchers from the University of Utah have gained new insight into the regulation of adult nerve cell generation in the hypothalamus, the part of the brain that regulates many aspects of behavior, mood, and metabolism.

11 Sep 2012

Intermittent hormone therapy effective for prostate cancer patients

Intermittent androgen deprivation is as effective as continuous therapy for men with rising prostate-specific antigen levels after primary or salvage radiotherapy, say researchers who believe the break from treatment improves quality of life.

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Baylor Health Care System raises awareness about atrial fibrillation

An estimated 2.5 million Americans suffer from irregular heartbeats-also known as atrial fibrillation. Baylor Health Care System is raising awareness about this often misunderstood, but potentially life changing cardiovascular condition whose incidence is on the rise and expected to more than double by 2050.

10 Sep 2012

Midwest pollen count hits new high

The Midwest's pollen count today hit a new high for the season. "Mold, weeds and ragweed are all high and also grass is high, which may surprise many people. The grass is corn grass and the high levels are caused by the seasonal harvesting of the corn as corn is a member of the botanical grass family," said Dr. Joseph Leija, who performs the Gottlieb Allergy Count, the official allergy count for the Midwest.

7 Sep 2012

A significant proportion of breast cancer survivors have chronic fatigue

UK study results show that over a third of breast cancer survivors have cancer-related fatigue syndrome and that these women have significantly lower subjective quality of life and mood than their nonfatigued peers.

6 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Longer looks: Too many pills for dad; Genetic secrets; A supermarket's dietitian

Job burnout can strike workers in nearly any field, but a new study finds that doctors are at special risk. Nearly 1 in 2 U.S. physicians report at least one symptom of burnout, with doctors at the front line of care particularly vulnerable, the study found -- a significantly higher rate than among the general working population.

1 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

Study reports flaws in design, analysis, and interpretation of Lyme disease

Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Study to investigate how breast cancer patients might benefit from exercise

Researchers in Edmonton and Calgary want to recruit 1,500 breast cancer patients over the next decade to find out how exercise and fitness affects cancer survival and recovery.

29 Aug 2012

Catheter ablation for Afib is safe and suppresses arrhythmia recurrences

Catheter ablation for atrial fibrillation (Afib) is safe and suppresses arrhythmia recurrences in 74% of patients after a single procedure, according to results from the one-year follow-up of the Atrial Fibrillation Ablation Pilot Study, the first European registry to evaluate the real-life epidemiology of catheter ablation for AFib.

29 Aug 2012

Study looks at exercise habits among cancer patients

Numerous studies have shown the powerful effect that exercise can have on cancer care and recovery. For patients who have gone through breast or colon cancer treatment, regular exercise has been found to reduce recurrence of the disease by up to 50 percent.

29 Aug 2012

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.

28 Aug 2012

Positive results from CardioKinetix’s Parachute device clinical trial on ischemic heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained low clinical events for patients with ischemic heart failure three years following Percutaneous Ventricular Restoration (PVR) therapy with the first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device.

28 Aug 2012